Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Bruker and 3M Collaborate for MALDI Imaging for Cancer Research

By BiotechDaily International staff writers
Posted on 14 Jun 2013
Bruker Corp. (Billerica, MA, USA) reported that it has signed an exclusive patent license agreement with 3M Company (Maplewood, MN, USA), which allows Bruker to include 3M patented technology related to matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging.

The licensed 3M patents are directed to a technique for performing mass spectrometry analysis on proteins in tissue that has been preserved in paraffin. The technology enables researchers to study formalin-fixed, paraffin-embedded (FFPE) tissue for drug development and life-science research.

MALDI imaging has been increasingly utilized to analyze clinically pertinent tissues such as tumor biopsies. The molecular phenotypes visualized by MALDI imaging have been demonstrated to correlate with parameters such as disease status or patient outcome, and have been effectively applied to the categorization of tissue samples.

MALDI imaging was first developed for the analysis of fresh, frozen tissue sections, however, the analysis of preserved FFPE tissue sections is becoming increasingly important due to methodological enhancements. In the MALDI imaging community, it is widely accepted that a meaningful analysis of FFPE tissue requires a pretreatment called antigen-retrieval.
Dr. Sören-Oliver Deininger, market manager for MALDI imaging at Bruker, stated, “The interest in the analysis of FFPE tissue by MALDI imaging is increasing strongly. Bruker has developed innovative technology to make MALDI imaging viable in histopathology by the integration of virtual microscopy and the possibility to classify tissue based on the molecular phenotypes [class-imaging]. Our license agreement with 3M shows our ongoing commitment to the MALDI imaging field, and gives our customers the necessary freedom to conduct their research and advance the field.”

MALDI imaging is suited to analyze biomarkers in tissue samples. By enabling histologic correlation of molecular phenotypes and correlation of molecular signals to clinical endpoints, the technology is an effective application for cancer research. It directly images metabolites, peptides, proteins, lipids, and drugs in FFPE samples with no antibodies, probes, fluorescent dyes, or radiolabels needed.

However, analysis can be complex, tiresome, and difficult to interpret. Bruker has developed special software that supports the entire workflow, including statistical analysis, providing simple and automated interpretation and reporting of results. This new agreement with 3M supports the continued development and use of this important enabling application.


Related Links:

Bruker
3M Company



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.